Author

I. Opitz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:development & morphogenesis· 1

Frequent Co-Authors

S. Hiltbrunner· 2 shared A. Curioni· 1 shared A. Curioni-Fontecedro· 1 shared A. Hariharan· 1 shared A. Ibanez· 1 shared A. Soltermann· 1 shared B. Bodenmiller· 1 shared B. Vrugt· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

S. Hiltbrunner

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Heterogeneity of RNA editing in mesothelioma and how RNA editing enzyme ADAR2 affects mesothelioma cell growth, response to chemotherapy and tumor microenvironment

A. Hariharan, W. Qi, H. Rehrauer, L. Wu, M. Ronner, M. Wipplinger, J. Kresoja-Rakic, S. Sun, L. Oton-Gonzales, M. Sculco, V. Serre-Beinier, C. Meiller, C. Blanquart, J.-F. Fonteneau, B. Vrugt, , E. Felley-Bosco

This study examines RNA editing heterogeneity in mesothelioma and shows ADAR2's role in cell growth, chemotherapy response, and tumor microenvironment regulation.

bioRxiv · Jul 12, 2022Cancer Biology

Acquired resistance to anti-PD1 therapy in patients with NSCLC reveals changes in T cell phenotypes and MET amplification

S. Hiltbrunner, L. Cords, S. Kasser, S. N. Freiberger, S. Kreutzer, N. C. Toussaint, L. Grob, I. Opitz, M. Messerli, M. Zoche, A. Soltermann, M. Rechsteiner, M. van den Broek, B. Bodenmiller, A. Curioni-Fontecedro

This study identifies two patterns of acquired resistance to anti-PD1 therapy in NSCLC patients, including reduced T cell infiltration and MET amplification.

bioRxiv · Apr 8, 2022 · PreprintCancer Biology

Coincidence detection of mitogenic signals via cytosolic pH regulates Cyclin D1 expression

L. M. Koch, E. Birkeland, S. Battaglioni, X. Helle, M. Meerang, S. Hiltbrunner, A. Ibanez, M. Peter, A. Curioni, I. Opitz, R. Dechant

The paper shows that elevated cytosolic pH regulates Cyclin D1 expression through E2F-dependent transcription and CREB1-p300/CBP interaction, linking pH changes to cell proliferation and cancer progression.

bioRxiv · Jul 15, 2020Cell Biology